Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
- None.
- None.
Namilumab is a therapeutic with significant potential for pulmonary sarcoidosis, a condition with limited effective treatments. By targeting GM-CSF, a cytokine implicated in inflammation and disease progression, the medication could fill a treatment void. For investors, the successful enrollment completion signals the company's ability to execute its clinical roadmap, which is key for maintaining investor confidence, especially in the biotech sector where clinical outcomes are critical.
As we look ahead to the topline results anticipated by the end of 2024, we should consider the market size and unmet need in this therapeutic area. Given the prevalence of sarcoidosis—200,000 in the U.S. and a larger global population—the addressable market could be substantial for Roivant and Kinevant Sciences, pending successful trial outcomes and eventual approval.
However, investors should be mindful of the inherent risks in biotech investing, particularly in clinical-stage companies. Delays, unexpected negative results, or regulatory hurdles could impact the company's valuation. It's important for investors to monitor the progression of the study and to be aware of the competitive landscape, as other treatments in development could affect the potential market share.
The announcement of completed enrollment in the RESOLVE-Lung study represents a milestone that's likely been factored into the valuation models for Roivant. Historically, biotech firms often see a rise in investor interest and share value as they make progress in their clinical trials. Keeping an eye on the company's burn rate and cash on hand is essential, as clinical studies are expensive undertakings that can quickly consume resources. We should also consider potential future financing needs or partnership deals, which could dilute existing shareholders but also bring additional expertise and resources.
In the run-up to releasing topline results, volatility is expected as investors speculate on the outcomes. A positive result could significantly uplift the company's stock, whereas failure could lead to a sharp decline. Diversification within an investment portfolio is one way to manage these risks. As with any clinical-stage biotech company, the potential reward must be weighed against the risk and investors should be prepared for all outcomes.
- Namilumab is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine believed to play a key role in the pathogenesis of sarcoidosis
- RESOLVE-Lung is a randomized, double-blind, placebo-controlled Phase 2 study designed to be supportive of registration that enrolled 107 pulmonary sarcoidosis patients whose disease is not well-controlled despite currently available treatments
- Topline results are expected by the end of calendar year 2024
“People living with pulmonary sarcoidosis clearly need new therapeutic options that can more safely and effectively control or resolve their disease,” said Bill Gerhart, CEO of Kinevant. “Completing enrollment for this study is an important milestone in our journey to develop a new therapy for those living with pulmonary sarcoidosis. I am grateful for the patients who volunteered to participate in the study, as well as for the extraordinary efforts of the Kinevant team, our industry partners, clinical trial site staff, and patient advocacy groups, all of whom came together to overcome the unique challenges of this disease to successfully enroll this study. We are very hopeful about the outcome, and we look forward to reporting topline results by the end of the year.”
Pulmonary sarcoidosis is a lung disease characterized by the presence of granulomas (clumps of immune cells) of unknown etiology that can cause breathlessness, fatigue, and pain. The resulting inflammation, if not effectively treated, can result in lung tissue scarring (fibrosis), lung dysfunction, and eventually lung failure. Approximately
Evidence from non-clinical studies indicate that GM-CSF is a key cytokine driving granuloma formation and inflammation in sarcoidosis, and that inhibiting GM-CSF can reduce granuloma activity and the resulting inflammation, leading potentially to a reduction in symptoms and resolution of the underlying disease. Namilumab is a potent inhibitor of GM-CSF that has been observed to be generally safe and well-tolerated in more than 350 participants across multiple clinical trials. Thus, namilumab has the potential to be the only well-tolerated and effective therapy for sarcoidosis, as well as the first therapy approved specifically for pulmonary sarcoidosis.
“Pulmonary sarcoidosis is a complex and challenging condition, with limited treatment options, and many unacceptable side effects. There is a need for new and better therapies to be developed,” said Mary McGowan, CEO of the Foundation for Sarcoidosis Research. “We are proud to have worked with Kinevant on the successful enrollment of this clinical trial. We are grateful to the sarcoidosis patient community who embraced this opportunity to lead us toward a potential new therapy as well as a deeper understanding of sarcoidosis.”
About RESOLVE-Lung
The RESOLVE-Lung study is a Phase 2 randomized, double-blind, placebo-controlled study of namilumab for the treatment of pulmonary sarcoidosis being conducted at multiple sites in the
About Namilumab
Namilumab is an investigational, fully human monoclonal antibody formulated to be conveniently administered once a month as a subcutaneous injection. Namilumab is a potent GM-CSF inhibitor that has been well-tolerated so far in more than 350 participants across multiple clinical trials. Evidence from non-clinical studies indicate that GM-CSF promotes macrophage and dendritic cell activity which contributes to granuloma formation. Inhibiting GM-CSF can reduce the presence of granulomas and the resulting inflammation, potentially leading to a reduction in symptoms and resolution of the underlying disease.
About Kinevant Sciences
Kinevant Sciences, a subsidiary of Roivant, is a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases. The company takes a patient-first approach to drug development, advancing candidates with the potential to resolve the underlying disease and create life-changing benefit for patients. Kinevant is initially focused on the development of namilumab for the treatment of sarcoidosis, a multi-organ systemic disease with a high unmet medical need. For more information, visit www.kinevant.com or follow us on LinkedIn.
About Roivant
Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant’s pipeline includes VTAMA®, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications; brepocitinib, a novel TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425073956/en/
Jennifer Arcure
Senior Vice President
Inizio Evoke Comms
Jennifer.Arcure@inizioevoke.com
Source: Kinevant Sciences
FAQ
What is the Phase 2 study by Roivant and Kinevant Sciences about?
What is namilumab and what does it target?
How many patients were enrolled in the RESOLVE-Lung study?
When are the topline results expected?
How many people are estimated to have sarcoidosis in the U.S.?
